Houstonian Chris Hunt and his wife, Ashton, created MedVendor to be a search platform that features up-to-date information for case workers for patients seeking at-home care. Photo via Getty Images

Anyone who has had to Google their way to home health care knows that it’s not the best way to get effective help. That’s where MedVendor comes in.

Houstonian Chris Hunt and his wife, Ashton, created MedVendor to be a search platform that features up-to-date information for caseworkers for case workers for patients seeking at-home care.

At the height of the COVID-19 pandemic, Chris Hunt was at a loss for how to help patients. He had recently taken on a new role in wound care sales. His company would send dressings directly to patients, but finding someone who could apply and change them was a different matter.

“It was an absolute nightmare using [Google] as a resource because you had all of these out-of-date listings. So it was a 50-50 shot whether that company would even be in business… And so it would be one in every seven, one in every eight calls that I would make that I could actually get ahold of somebody that I could talk to about wound care services,” Chris Hunt recalls.

In 2020, the couple began interviewing developers to take their idea to reality. They incorporated as an LLC in 2021.

Chris Hunt calls the platform a home-care equivalent to Angie’s List or Yelp. Though it’s currently designed for users in the medical field, he says that they are working on crafting MedVendor to be used by the general public as well.

Users input the type of service they’re looking for, then can select multiple individual patient needs to further tailor the search. “It'll give you a short list from that of companies that can service those criteria. And once you've been given that list, then you can filter patient zip code as well as patient insurance plan to then whittle that search further and really get to a granular level in terms of what resources that you want to find,” Chris Hunt explains.

The couple says that their Houston location has been both a blessing and a curse for their burgeoning business, which released the MedVendor platform on October 1. Though Chris Hunt says that cutting his business’ teeth in Southeast Texas, with its expansive medical community “proves your worth and holds a ton of weight. There you can go to other markets and really capitalize.”

However, MedVendor doesn’t want to be known just as a Texas company — the Hunts hope to expand far beyond the Houston area to eventually become a household name.

Ashton Hunt, who was also in medical sales before the couple took the leap to pursue MedVendor full-time, is marketing director for the company. She adds that in Q4 of this year, they plan to release a phone app version of the platform, which will make using it even easier for medical teams.

“Ideally, a case manager or social worker, if they're working on a discharge plan for a patient, they can even be bedside with them with their phone to help find some resources to then pass along to the family or the caregiver,” Chris Hunt says.

Ultimately, the goal of the company, the couple says, is to open up possibilities for patients. By providing up-to-date, vetted information, the hope is that MedVendor will not only supply them with the care they need, but educate them in the process.

- YouTubewww.youtube.com

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."